Physician profile
Ron E Loomis
NPI 1740054469
$4,524.94
in general payments reported to CMS, 2019-2025
28 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $117 · 2024: $1,712 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,524.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,057.28 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $610.15 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $522.75 | 2024-2025 | Evenity, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $297.80 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.62 | 2024-2025 | Xifaxan, Trulance |
| Medtronic, INC. | $264.24 | 2024-2025 | Abre, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Edwards Lifesciences Corporation | $249.82 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $206.29 | 2024-2025 | Jardiance, Mounjaro, Kisunla |
| Phathom Pharmaceuticals, INC. | $148.51 | 2024 | Voquezna |
| Astellas Pharma US INC | $134.07 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.31 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $112.97 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $92.49 | 2024-2025 | |
| Corcept Therapeutics | $80.10 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $60.94 | 2025 | Inspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.74 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $27.22 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.35 | 2024 | Keveyis |
| Cmp Pharma, INC. | $24.08 | 2024 | Liqrev, Tadliq, Carospir |
| Merck Sharp & Dohme LLC | $23.91 | 2025 | Capvaxive, Gardasil 9 |
| Aimmune Therapeutics, INC. | $22.69 | 2025 | Zenpep |
| Organogenesis INC. | $21.89 | 2025 | Puraply Wound Matrix |
| Exact Sciences Corporation | $21.71 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $20.72 | 2025 | Watchman Flx |
| Inogen, INC. | $20.26 | 2025 | |
| Abbvie INC. | $18.57 | 2024 | |
| Painteq LLC | $17.25 | 2024 | Painteq |
| Scilex Pharmaceuticals INC. | $16.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Loomis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.